1. Home
  2. MELI vs SNY Comparison

MELI vs SNY Comparison

Compare MELI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MercadoLibre Inc.

MELI

MercadoLibre Inc.

HOLD

Current Price

$1,635.70

Market Cap

94.0B

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$42.59

Market Cap

104.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MELI
SNY
Founded
1999
1994
Country
Uruguay
France
Employees
N/A
74846
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.0B
104.5B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
MELI
SNY
Price
$1,635.70
$42.59
Analyst Decision
Strong Buy
Buy
Analyst Count
17
5
Target Price
$2,666.47
$58.00
AVG Volume (30 Days)
489.1K
2.2M
Earning Date
05-04-2026
04-23-2026
Dividend Yield
N/A
3.47%
EPS Growth
4.54
N/A
EPS
8.23
N/A
Revenue
$28,893,000,000.00
N/A
Revenue This Year
$36.23
$3.49
Revenue Next Year
$24.20
$6.10
P/E Ratio
$203.07
$6.14
Revenue Growth
39.06
N/A
52 Week Low
$1,495.00
$42.28
52 Week High
$2,645.22
$52.68

Technical Indicators

Market Signals
Indicator
MELI
SNY
Relative Strength Index (RSI) 47.36 41.49
Support Level $1,626.21 $42.30
Resistance Level $1,733.78 $48.76
Average True Range (ATR) 57.40 0.60
MACD 5.04 0.00
Stochastic Oscillator 47.50 11.49

Price Performance

Historical Comparison
MELI
SNY

About MELI MercadoLibre Inc.

MercadoLibre is the largest e-commerce marketplace in Latin America, with more than 120 million unique active buyers and 1 million active sellers at the end of 2025. The company is roughly split between its e-commerce business, which includes its fulfillment and advertising services, and its fintech segment, which comprises its rapidly expanding payment and digital wallet platform (Mercado Pago) and its lending business (Mercado Credito). While the company operates in 18 countries, its primary markets are Brazil, Argentina, and Mexico, which account for more than 95% of its revenue.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: